ArticlebioRxiv : the preprint server for biology2025
Top-DTI: Integrating Topological Deep Learning and Large Language Models for Drug Target Interaction Prediction.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
2 authors.
Funding
Abstract
Motivation: The accurate prediction of drug-target interactions (DTI) is a crucial step in drug discovery, providing a foundation for identifying novel therapeutics. Traditional drug development is both costly and time-consuming, often spanning over a decade. Computational approaches help narrow the pool of compound candidates, offering significant starting points for experimental validation. In this study, we propose Top-DTI framework for predicting DTI by integrating topological data analysis (TDA) with large language models (LLMs). Top-DTI leverages persistent homology to extract topological features from protein contact maps and drug molecular images. Simultaneously, protein and drug LLMs generate semantically rich embeddings that capture sequential and contextual information from protein sequences and drug SMILES strings. By combining these complementary features, Top-DTI enhances predictive performance and robustness. Results: Experimental results on the public BioSNAP and Human DTI benchmark datasets demonstrate that the proposed Top-DTI model outperforms state-of-the-art approaches across multiple evaluation metrics, including AUROC, AUPRC, sensitivity, and specificity. Furthermore, the Top-DTI model achieves superior performance in the challenging cold-split scenario, where the test and validation sets contain drugs or targets absent from the training set. This setting simulates real-world scenarios and highlights the robustness of the model. Notably, incorporating topological features alongside LLM embeddings significantly improves predictive performance, underscoring the value of integrating structural and sequence-based representations. Availability: The data and source code of Top-DTI is available at https://github.com/bozdaglab/Top_DTI under Creative Commons Attribution Non Commercial 4.0 International Public License.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.